The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through smodulating FGF8 and VEGF

Carcinogenesis

Volumn 35, Issue 5, 2014, Pages 1144-1153

  Liu, Fabao ^a   You, Xiaona ^a   Wang, Yue ^a   Liu, Qian ^a   Liu, Yunxia ^a   Zhang, Shuqin ^a   Chen, Lingyi ^a   Zhang, Xiaodong ^a   Ye, Lihong ^a  

^a NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FIBROBLAST GROWTH FACTOR 8; HEMOGLOBIN; HEPATITIS B X INTERACTING PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MICRORNA; MIRNA 503; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN;

3' UNTRANSLATED REGION; ANGIOGENESIS; ANGIOGENESIS ASSAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MATRIGEL ANGIOGENESIS ASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLAST GROWTH FACTOR 8; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84901978765     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu021     Document Type: Article

References (50)

1. Carmeliet, P. (2005) Angiogenesis in life, disease and medicine. Nature, 438, 932-936.
2. Weis, S.M. et al. (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med., 17, 1359-1370.
3. Turner, N. et al. (2010) Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer, 10, 116-129.
4. Sonvilla, G. et al. (2008) FGF18 in colorectal tumour cells: autocrine and paracrine effects. Carcinogenesis, 29, 15-24.
5. Wesche, J. et al. (2011) Fibroblast growth factors and their receptors in cancer. Biochem. J., 437, 199-213.
6. Tanaka, A. et al. (1992) Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells. Proc. Natl Acad. Sci. USA, 89, 8928-8932.
7. Tanaka, A. et al. (1998) High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res., 58, 2053-2056.
8. Marsh, S.K. et al. (1999) Increased expression of fibroblast growth factor 8 in human breast cancer. Oncogene, 18, 1053-1060.
9. Ruohola, J.K. et al. (2001) Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res., 61, 4229-4237.
10. Tuomela, J. et al. (2010) Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts. BMC Cancer, 10, 596.
11. Linderholm, B.K. et al. (2009) Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann. Oncol., 20, 1639-1646.
12. Shenoy, S.K. et al. (2012) ß-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. Oncogene, 31, 282-292.
13. Presta, M. et al. (2005) Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev., 16, 159-178.
14. Shi, Y.H. et al. (2005) In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI-3K/Akt and MEK1/ERK pathways. J. Pathol., 205, 530-536.
15. Ferrara, N. (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev., 25, 581-611.
16. Kano, M.R. et al. (2005) VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J. Cell Sci., 118(Pt 16), 3759-3768.
17. Lieu, C. et al. (2011) Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin. Cancer Res., 17, 6130-6139.
18. Melegari, M. et al. (1998) Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication. J. Virol., 72, 1737-1743.
19. Marusawa, H. et al. (2003) HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J., 22, 2729-2740.
20. Fujii, R. et al. (2006) HBXIP, cellular target of hepatitis B virus oncoprotein, is a regulator of centrosome dynamics and cytokinesis. Cancer Res., 66, 9099-9107.
21. Bar-Peled, L. et al. (2012) Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1. Cell, 150, 1196-1208.
22. Wang, F. et al. (2012) Overexpression of hepatitis B x-interacting protein in HepG2 cells enhances tumor-induced angiogenesis. Mol. Cell. Biochem., 364, 165-171.
23. Liu, S. et al. (2012) The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells. J. Biol. Chem., 287, 30228-30239.
24. Yue, L. et al. (2013) The oncoprotein HBXIP activates transcriptional coregulatory protein LMO4 via Sp1 to promote proliferation of breast cancer cells. Carcinogenesis, 34, 927-935.
25. Xu, F. et al. (2013) The oncoprotein HBXIP up-regulates Skp2 via activating transcription factor E2F1 to promote proliferation of breast cancer cells. Cancer Lett., 333, 124-132.
26. Liu, Q. et al. (2013) The oncoprotein HBXIP upregulates Lin28B via activating TF II D to promote proliferation of breast cancer cells. Int. J. Cancer, 133, 1310-1322.
27. Zhang, Y. et al. (2013) The nuclear import of oncoprotein hepatitis B X-interacting protein depends on interacting with c-Fos and phosphorylation of both proteins in breast cancer cells. J. Biol. Chem., 288, 18961-18974.
28. Hu, N. et al. (2011) miR-520b regulates migration of breast cancer cells by targeting hepatitis B X-interacting protein and interleukin-8. J. Biol. Chem., 286, 13714-13722.
29. Kanno, E. et al. (2010) Comprehensive screening for novel rab-binding proteins by GST pull-down assay using 60 different mammalian Rabs. Traffic, 11, 491-507.
30. Zhang, Y. et al. (2011) PGE2 promotes angiogenesis through EP4 and PKA Cγ pathway. Blood, 118, 5355-5364.
31. Shao, R. et al. (2004) Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol. Cell. Biol., 24, 3992-4003.
32. Wen, Y. et al. (2008) Interaction of hepatitis B viral oncoprotein with cellular target HBXIP dysregulates centrosome dynamics and mitotic spindle formation. J. Biol. Chem., 283, 2793-2803.
33. Zhou, B. et al. (2013) MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett., 333, 159-169.
34. Tarkkonen, K. et al. (2010) Fibroblast growth factor 8 induced downregulation of thrombospondin 1 is mediated by the MEK/ERK and PI3K pathways in breast cancer cells. Growth Factors, 28, 256-267.
35. Kimbro, K.S. et al. (2006) Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr. Relat. Cancer, 13, 739-749.
36. Liu, Y. et al. (1995) Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ. Res., 77, 638-643.
37. Atlas, E. et al. (2001) A CREB site in the BRCA1 proximal promoter acts as a constitutive transcriptional element. Oncogene, 20, 7110-7114.
38. Wilson, B.E. et al. (1996) Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol. Cell. Biol., 16, 5546-5556.
39. Boulon, S. et al. (2002) Oct-1 potentiates CREB-driven cyclin D1 promoter activation via a phospho-CREB- and CREB binding protein-independent mechanism. Mol. Cell. Biol., 22, 7769-7779.
40. Conkright, M.D. et al. (2003) Genome-wide analysis of CREB target genes reveals a core promoter requirement for cAMP responsiveness. Mol. Cell, 11, 1101-1108.
41. Rissland, O.S. et al. (2011) MicroRNA destabilization enables dynamic regulation of the miR-16 family in response to cell-cycle changes. Mol. Cell, 43, 993-1004.
42. Caporali, A. et al. (2011) Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation, 123, 282-291.
43. Tsunoda, S. et al. (2007) Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization. Cancer Sci., 98, 541-548.
44. Jia, W. et al. (2013) S100A4 silencing suppresses proliferation, angiogenesis and invasion of thyroid cancer cells through downregulation of MMP-9 and VEGF. Eur. Rev. Med. Pharmacol. Sci., 17, 1495-1508.
45. Ravi, R. et al. (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev., 14, 34-44.
46. Montañez-Wiscovich, M.E. et al. (2009) LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression. Oncogene, 28, 3608-3618.
47. Zhou, X. et al. (2012) LMO4 inhibits p53-mediated proliferative inhibition of breast cancer cells through interacting p53. Life Sci., 91, 358-363.
48. Chang, T.C. et al. (2009) Lin-28B transactivation is necessary for Mycmediated let-7 repression and proliferation. Proc. Natl Acad. Sci. USA, 106, 3384-3389.
49. Tsai, W.B. et al. (2012) Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res., 72, 2622-2633.
50. Barh, D. (2008) Let-7 replacement therapy: applicability in cancer. Cancer Ther., 6, 969-984.